Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. 1985

D K Yu, and W F Elmquist, and R J Sawchuk

The pharmacokinetics of propylene glycol has been examined during multiple oral-dosing regimens. The glycol is rapidly absorbed, with Cpmax observed within 1 h following administration. The terminal elimination half-life is approximately 4 h. After a minimum of 10 half-lives of maintenance dosing on a fixed regimen, the accumulation of propylene glycol differed significantly among individuals because of variability in apparent clearance. The average apparent total body clearance is approximately 0.1 L/kg X h and may be concentration dependent. The apparent volume of distribution is approximately 0.5 L/kg, approximating total body water.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011409 Propylene Glycols Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations. Propanediols,Glycols, Propylene
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

D K Yu, and W F Elmquist, and R J Sawchuk
September 1987, Therapeutic drug monitoring,
D K Yu, and W F Elmquist, and R J Sawchuk
June 1998, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
D K Yu, and W F Elmquist, and R J Sawchuk
October 1987, Journal of pharmacokinetics and biopharmaceutics,
D K Yu, and W F Elmquist, and R J Sawchuk
June 1996, Pharmacy world & science : PWS,
D K Yu, and W F Elmquist, and R J Sawchuk
January 1982, European journal of drug metabolism and pharmacokinetics,
D K Yu, and W F Elmquist, and R J Sawchuk
January 1991, Food additives and contaminants,
D K Yu, and W F Elmquist, and R J Sawchuk
August 1993, Journal of pharmacokinetics and biopharmaceutics,
D K Yu, and W F Elmquist, and R J Sawchuk
April 1976, Journal of pharmacokinetics and biopharmaceutics,
D K Yu, and W F Elmquist, and R J Sawchuk
January 2013, British journal of clinical pharmacology,
D K Yu, and W F Elmquist, and R J Sawchuk
May 1987, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!